ACTOS Not Associated With Increased Risk Of Heart Attack, Stroke, Or Death: Takeda Statement Published In JAMA

Takeda Pharmaceuticals North America, Inc. is aware of the review of ACTOS® (pioglitazone HCl) data conducted by A. Michael Lincoff, M.D., and colleagues at the Cleveland Clinic, published in the Journal of the American Medical Association which concluded that ACTOS is associated with a significantly lower risk of heart attack, stroke, or death among a diverse population of 16,390 patients with diabetes versus control therapy. [click link for full article]

More: continued here

Filed under: Diabetes on September 20th, 2007